I don't have enough medical brain power to understand so ask your doctor for it in understandable terms. So you can ask whether better stroke recovery is more important than calcifying your arteries.
Simvastatin attenuates axonal injury after experimental traumatic brain injury and promotes neurite outgrowth of primary cortical neurons Oct. 2012
Or these competing narratives;
Statins associated with improved heart structure and function May 2017
Stroke Rounds: Statin Users Have Better Outcomes February 2016
Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke
September 2011
New study strengthens evidence of the connection between statin use and cataracts December 2014
Stroke Patients Boost Survival by Getting Statins in Hospital October 2014
Statin Medication Enhances Progression of Coronary Artery Calcification: The Heinz Nixdorf Recall Study
Under an Elsevier user license
open archive
Statins are suggested to stabilize plaque by decreasing lipid-rich and necrotic plaque components and increasing plaque calcification 1, 2. However, to date the relationship between statin administration and progression of coronary artery calcification (CAC) is poorly understood, and existing data are limited to patient cohorts and relatively short follow-up
times. Therefore, in this study, we aimed to investigate whether the
use of statins influences the progression of CAC during >5 years of
follow-up in an observational study based on participants from the
general population cohort of the Heinz Nixdorf Recall Study, free from
clinical cardiovascular disease at baseline (3). CAC score was assessed using electron-beam computed tomography at baseline and after 5 years using an identical scanning protocol and quantified by the Agatston score. Regression analysis
was used to determine the association of CAC progression with statin
intake, with log transformation of CAC to normalize for its
distribution.
We included 3,483 participants (mean age 59 ± 8 years, 47% men) in this analysis. Overall, 230 subjects received statin medications at baseline. Median CAC scores
at baseline were 58.8 (interquartile range [IQR]: 2.6 to 273.3) for
subjects with statin intake and 5.9 (IQR: 0 to 80.2) for subjects
without. Median follow-up CAC scores were 141.3 (IQR: 19.6 to 554.7) for subjects with statin intake and 21.2 (IQR: 0.0 to 174.6) for those without.
In unadjusted regression analysis, taking a statin was associated with 39% higher progression in CAC+1 (Table 1). This relationship was slightly attenuated after adjustment for cardiovascular risk factors
but remained statistically significant, with approximately 31% higher
progression of CAC+1, attributable to statin intake. Likewise, subjects
with statin intake had almost 2-fold odds for CAC progression greater
than the expected range compared with subjects without statin medication in unadjusted and adjusted regression analyses.
Tables and more at link.
No comments:
Post a Comment